Werewolf Therapeutics Shares Outstanding History (HOWL)
Werewolf Therapeutics reported 48.6M shares outstanding at the end of fiscal 2025.
View full Werewolf Therapeutics company overviewWerewolf Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 48.6M | 3.8M | +8.41% |
| 2024 | 2024-12-31 | 44.8M | 5.7M | +14.63% |
| 2023 | 2023-12-31 | 39.1M | 7.7M | +24.41% |
| 2022 | 2022-12-31 | 31.4M | 4.1M | +15.09% |
| 2021 | 2021-12-31 | 27.3M | 26.1M | +2206.84% |
| 2020 | 2020-12-31 | 1.2M | — | — |
Werewolf Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 48.6M | 3.3M | +7.20% |
| Q1 2026 | 2026-03-31 | 48.6M | 3.8M | +8.41% |
| Q4 2025 | 2025-12-31 | 48.6M | 3.8M | +8.41% |
| Q3 2025 | 2025-09-30 | 47.3M | 3.6M | +8.12% |
| Q2 2025 | 2025-06-30 | 45.3M | 1.6M | +3.74% |
| Q1 2025 | 2025-03-31 | 44.8M | 1.5M | +3.57% |
| Q4 2024 | 2024-12-31 | 44.8M | 5.7M | +14.63% |
| Q3 2024 | 2024-09-30 | 43.7M | 8.1M | +22.61% |
| Q2 2024 | 2024-06-30 | 43.7M | 8.1M | +22.61% |
| Q1 2024 | 2024-03-31 | 43.3M | 8.0M | +22.61% |
| Q4 2023 | 2023-12-31 | 39.1M | 7.7M | +24.41% |
| Q3 2023 | 2023-09-30 | 35.7M | 5.0M | +16.49% |
| Q2 2023 | 2023-06-30 | 35.6M | 7.4M | +26.04% |
| Q1 2023 | 2023-03-31 | 35.3M | 7.9M | +28.74% |
| Q4 2022 | 2022-12-31 | 31.4M | 4.1M | +15.09% |
| Q3 2022 | 2022-09-30 | 30.6M | 3.4M | +12.46% |
| Q2 2022 | 2022-06-30 | 28.3M | 1.1M | +4.22% |
| Q1 2022 | 2022-03-31 | 27.4M | 25.7M | +1457.95% |
| Q4 2021 | 2021-12-31 | 27.3M | 25.6M | +1464.32% |
| Q3 2021 | 2021-09-30 | 27.2M | — | — |
| Q2 2021 | 2021-06-30 | 27.1M | — | — |
| Q1 2021 | 2021-03-31 | 1.8M | — | — |
| Q4 2020 | 2020-12-31 | 1.7M | — | — |
Werewolf Therapeutics shares outstanding trends
Over the last five reported fiscal years, Werewolf Therapeutics's shares outstanding moved from 1.2M to 48.6M, a change of 47.4M. The latest reported quarter, Q2 2026, shows 48.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Werewolf Therapeutics filings at SEC.gov ↗